Microscopic proteins such as helicopter identification monitor DNA repair:
The DNA of the human body is always damaged, and it is always repaired by the body’s repair mechanism. If there is no such repair mechanism, cancer will ravage the human body. A recent study found that an anti-UV protein has far more than just sun protection – the protein is responsible for “patrolling” looking for damaged DNA, finding a “construction team” and “monitoring” the repair.
A recent one published in Nature. A study in the journal Nature Structural and Molecular Biology found that “binding UV-damaged DNA proteins” (UV-DDB) surveyed damaged DNA in the human microscopic like a “helicopter.”
Bennett Van Houten, a lead author of the study and professor of pharmacology and biochemistry at the University of Pittsburgh, said: “If you want to fix a hole in the pavement, you have to find it first. UV-DDB plays such a role. It found broken DNA and attracted other members to repair the damage.”
Van Houten says it’s not easy to search for damage in 3 billion base pairs that are only a few microns wide. In addition to the large range of searches, these base pairs are closely packed and many molecules are inaccessible.
Following the metaphor of the pavement, Van Houten said that one possible strategy is to walk along the road to see the potholes; another way is to look at the helicopter. However, because the molecules “can’t see” the road surface, UV-DDB combines two strategies to find damage.
“UV-DDB is like a helicopter that can land and look at a few blocks. It has the ability to help DNA repair molecules find damage that they can’t find and hide inside the chromosome.”
Van Houten said that using single-molecule imaging technology, this is the first study to observe the working mechanism of repair proteins in the micro.
The researchers said the findings of the study helped explain why children born with UV-DDB are almost completely immune to skin cancer when exposed to sunlight ; on the other hand, why UV-DDB levels are higher. High cancer patients respond better to anticancer therapies.